Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan-Reference-Cited by-同舟云学术

Dapagliflozin Utilization in Chronic Kidney Disease and Its Real-World Effectiveness Among Patients with Lower Levels of Albuminuria in the USA and Japan

Published:2024-01-19 Issue:3 Volume:41 Page:1151-1167
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Tangri Navdeep,Rastogi Anjay,Nekeman-Nan Cassandra^ORCID,Hong Lai San,Ozaki Asuka,Franzén Stefan,Sofue Tadashi

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02773-x.pdf

Reference36 articles.

1. Sundström J, Bodegard J, Bollmann A, et al. Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 24 million patients from 11 countries: the CaReMe CKD study. Lancet Reg Health Eur. 2022;20:100438.

2. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048–50.

3. Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020;16(5):251.

4. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52.

5. Verberne WR, Das-Gupta Z, Allegretti AS, et al. Development of an international standard set of value-based outcome measures for patients with chronic kidney disease: a report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. Am J Kidney Dis. 2019;73(3):372–84.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SGLT2 Inhibitor Use in Chronic Kidney Disease: Supporting Cardiovascular, Kidney, and Metabolic Health;Kidney Medicine;2024-08

2. A review of the latest real‐world evidence studies in diabetic kidney disease: What have we learned about clinical practice and the clinical effectiveness of interventions?;Diabetes, Obesity and Metabolism;2024-06-20

3. Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD);Clinical Kidney Journal;2024-04-04

4. Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists;Journal of Primary Care & Community Health;2024-01